A phase I study of active specific intralymphatic immunotherapy (ASILI)

Area of Science:

• Oncology
• Immunotherapy
• Clinical Trials

Background:

• Advanced malignancies often lack effective treatment options.
• Conventional therapies may be exhausted or refused by patients.
• Novel immunotherapeutic approaches are needed for refractory cancers.

Purpose of the Study:

• To evaluate the safety and immunogenicity of active specific intralymphatic immunotherapy (ASILI) in patients with advanced malignancies.
• To assess the preliminary efficacy of ASILI in terms of tumor response.
• To explore the immunological effects of ASILI on patient immune cells.

Main Methods:

• Phase I toxicology trial involving 21 patients with advanced cancers.
• Patients received intralymphatic injections of irradiated tumor cells monthly.
• No other anti-neoplastic treatments were administered concurrently.

Main Results:

• ASILI was well-tolerated with minimal adverse events, except for one case of bacterial lymphangitis.
• The treatment induced positive delayed hypersensitivity reactions to recall antigens and immunizing tumor cells in most patients.
• Objective tumor regression was observed in 5 of 19 evaluable patients, with 6 showing stabilization.

Conclusions:

• Active specific intralymphatic immunotherapy (ASILI) is a safe and immunogenic treatment for advanced malignancies.
• ASILI demonstrates potential anti-tumor activity, warranting further investigation in larger trials.
• This immunotherapy approach offers a new avenue for patients with refractory cancers.